Research Status.
Semax and Selank are synthetic peptide compounds that have been investigated in neurological, molecular and behavioural research.
Although the two compounds are frequently grouped together, they originate from different peptide sequences and have developed distinct research profiles.
Semax is derived from a fragment of adrenocorticotropic hormone (ACTH), while Selank was developed from the naturally occurring immunomodulatory peptide tuftsin.
Both compounds have been investigated primarily through preclinical, molecular and animal research, with a smaller body of human research originating predominantly from Russia.
Neither compound should be regarded as interchangeable simply because they appear within similar areas of peptide research.
⸻
Semax and Selank at a Glance
Semax
Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
Peptide length: 7 amino acids
Origin: ACTH-derived synthetic peptide
Primary research areas: neurotrophic signalling, gene expression, neural stress and experimental cerebral-ischaemia models.
Selank
Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
Peptide length: 7 amino acids
Origin: synthetic analogue derived from tuftsin
Primary research areas: stress-response models, neurotransmitter signalling, gene expression and behavioural research.
Both compounds contain a Pro-Gly-Pro sequence but originate from different parent peptides and should therefore be evaluated independently.
⸻
What Is Semax?
Semax is a synthetic heptapeptide developed from an ACTH-derived peptide sequence.
Unlike the complete ACTH hormone, Semax was designed as a short peptide analogue and has subsequently been investigated in a variety of experimental neurological models.
Research involving Semax has examined several biological processes, including neurotrophin-associated signalling, gene-expression changes and cellular responses following experimental neurological stress.
One particularly studied area involves brain-derived neurotrophic factor (BDNF).
Experimental studies in animal models have reported changes in BDNF-associated measurements following exposure to Semax.
Researchers have also examined genome-wide changes in gene expression following Semax administration in experimental models of focal cerebral ischaemia.
These findings have contributed to continued interest in Semax as an experimental compound for investigating neural signalling pathways.
⸻
What Is Selank?
Selank is also a synthetic heptapeptide, but its molecular origin differs substantially from Semax.
Selank was developed from tuftsin, a naturally occurring tetrapeptide involved in immune-related biological processes.
Its sequence incorporates the tuftsin-derived structure together with additional amino acids.
Research involving Selank has explored several areas, including neurotransmitter-related signalling, stress-response pathways, gene expression and behavioural models.
Animal studies have investigated Selank under experimental chronic-stress conditions, while other research has examined changes in gene expression associated with exposure to the peptide.
These studies have resulted in a research profile that is distinct from the predominantly neurotrophic and cerebral-ischaemia-related literature associated with Semax.
⸻
Structural Differences
Although both Semax and Selank contain seven amino acids, their underlying sequences are different.
Semax:
Met-Glu-His-Phe-Pro-Gly-Pro
Selank:
Thr-Lys-Pro-Arg-Pro-Gly-Pro
The final Pro-Gly-Pro portion is shared between the two peptides.
However, the initial amino-acid sequences originate from entirely different biological peptides.
Semax originates from ACTH-related research, whereas Selank originates from tuftsin-related research.
This distinction is important because structural similarity alone does not establish identical biological activity.
⸻
Research Mechanisms Under Investigation
Semax
Research involving Semax has examined several potential biological mechanisms.
These include:
● neurotrophin-associated signalling
● BDNF-related pathways
● transcriptional and gene-expression changes
● neuronal responses to experimental stress
● molecular changes following experimentally induced cerebral ischaemia
Genome-wide expression studies have demonstrated that Semax may influence multiple groups of genes in experimental animal models.
However, identifying changes in gene expression does not establish a clinical effect.
These findings instead provide researchers with potential molecular pathways for further investigation.
Selank
Research involving Selank has concentrated on a somewhat different group of biological systems.
Areas investigated include:
● neurotransmitter-associated signalling
● stress-response pathways
● gene-expression regulation
● immune-related signalling
● behavioural responses in experimental animal models
Some studies have examined Selank in chronic-stress models and compared experimental responses with established pharmacological compounds.
Again, these findings should be interpreted within the experimental models in which they were produced.
⸻
Semax vs Selank: Key Research Differences
The most important distinction between Semax and Selank is not which compound is “better”, but rather which biological questions researchers have investigated with each compound.
Semax research has placed considerable emphasis on neurotrophic signalling, BDNF-associated measurements and molecular responses following neurological stress or experimental cerebral ischaemia.
Selank research has more frequently examined stress-related behavioural models, neurotransmitter-associated mechanisms and gene-expression changes.
There is some overlap between these research areas, particularly in studies examining neurological signalling.
However, evidence obtained from one compound cannot automatically be applied to the other.
⸻
Are Semax and Selank Interchangeable?
Current research does not support treating Semax and Selank as interchangeable compounds.
Although they are both synthetic heptapeptides and share part of their amino-acid sequence, they originate from different parent peptides.
Their published research also focuses on different experimental questions.
For laboratory research, compound selection should therefore be determined by the specific molecular pathway, experimental model or research hypothesis being investigated.
⸻
Evidence Base
A significant limitation affecting both Semax and Selank research is the nature of the available evidence.
Much of the published literature consists of:
● animal studies
● molecular investigations
● gene-expression studies
● experimental neurological models
● relatively small or geographically concentrated human studies
A substantial portion of the research originates from Russian research institutions and publications.
Independent large-scale replication remains limited compared with established pharmaceutical compounds.
Consequently, results obtained from experimental models should not automatically be extrapolated to humans.
⸻
Human Research
Human studies involving Semax and Selank have been reported in the scientific literature.
However, the human evidence base remains considerably smaller and less independently replicated than the preclinical literature.
Differences in study design, participant populations, research methodology and publication accessibility also make broad conclusions difficult.
Human findings should therefore be considered preliminary and evaluated independently from animal and molecular research.
⸻
Current Research Limitations
Several limitations should be considered when reviewing the Semax and Selank literature.
These include limited independent replication, relatively small human datasets, variation between experimental models and the concentration of much of the published research within a limited number of research groups.
Animal behavioural findings also cannot establish equivalent effects in humans.
Similarly, changes in BDNF, gene expression or neurotransmitter-related measurements demonstrate biological activity within a particular experimental system but do not by themselves establish therapeutic effectiveness.
Further independently replicated research would be required to clarify the biological significance of many reported findings.
⸻
Semax vs Selank: Research Summary
Semax and Selank are structurally distinct synthetic peptides with different biological origins and research histories.
Semax is derived from an ACTH-related peptide sequence and has been investigated extensively in neurotrophic signalling, gene-expression and experimental neurological-stress models.
Selank originates from the tuftsin peptide sequence and has been investigated in stress-response, neurotransmitter, behavioural and gene-expression research.
Although the compounds share certain structural characteristics, current evidence does not justify treating them as equivalent.
The most scientifically appropriate comparison therefore concerns their different experimental applications and molecular research pathways, rather than attempting to determine which compound is superior.
⸻
References
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analogue of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006.
Medvedeva EV, Dmitrieva VG, Povarova OV, et al. Effect of Semax on the genome-wide profile of gene expression in the rat brain focal ischemia model. BMC Genomics. 2014;15:228.
Kasian A, Shcherbakova K, Barygin O, et al. Effects of Selank and diazepam on behavioural responses in experimental models. Behavioural Neurology. 2017.
Additional published Semax and Selank literature can be located through PubMed and other scientific literature databases.
⸻
Research Use Only
This article is provided solely as an educational summary of published scientific research.
Products referenced by Evolve Peptides UK are supplied strictly for laboratory and scientific research purposes only.
They are not intended for human or veterinary use, consumption, administration, diagnosis, treatment or prevention of disease.
Nothing contained within this article constitutes medical advice or a recommendation for use.
